376 related articles for article (PubMed ID: 17582802)
1. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
[TBL] [Abstract][Full Text] [Related]
2. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
Yokoyama Y; Xin B; Shigeto T; Mizunuma H
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.
Shigeto T; Yokoyama Y; Xin B; Mizunuma H
Oncol Rep; 2007 Oct; 18(4):833-40. PubMed ID: 17786343
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers.
Xin B; Yokoyama Y; Shigeto T; Mizunuma H
Pathol Oncol Res; 2007; 13(4):365-9. PubMed ID: 18158574
[TBL] [Abstract][Full Text] [Related]
5. Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer.
Yokoyama Y; Xin B; Shigeto T; Umemoto M; Kasai-Sakamoto A; Futagami M; Tsuchida S; Al-Mulla F; Mizunuma H
Mol Cancer Ther; 2007 Apr; 6(4):1379-86. PubMed ID: 17431116
[TBL] [Abstract][Full Text] [Related]
6. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.
Hazra S; Dubinett SM
Prostaglandins Leukot Essent Fatty Acids; 2007 Jul; 77(1):51-8. PubMed ID: 17697767
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
8. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes.
Naruse T; Nishida Y; Hosono K; Ishiguro N
Carcinogenesis; 2006 Mar; 27(3):584-92. PubMed ID: 16219634
[TBL] [Abstract][Full Text] [Related]
9. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma.
Shaik MS; Chatterjee A; Singh M
Clin Cancer Res; 2004 Feb; 10(4):1521-9. PubMed ID: 14977856
[TBL] [Abstract][Full Text] [Related]
10. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells.
Li J; Chen X; Dong X; Xu Z; Jiang H; Sun X
J Gastroenterol Hepatol; 2006 Dec; 21(12):1814-20. PubMed ID: 17074019
[TBL] [Abstract][Full Text] [Related]
11. [Ciglitazone inhibits growth of lung cancer cells A549 in vitro and in vivo: an experimental study].
Zhang HL; Zhang ZX; Xu YJ
Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):531-4. PubMed ID: 15555282
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA
Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
14. The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo.
Liu JF; Zhang SW; Jamieson GG; Zhu GJ; Wu TC; Zhu TN; Shan BE; Drew PA
Int J Cancer; 2008 Apr; 122(7):1639-44. PubMed ID: 18058818
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma is required for the inhibitory effect of ciglitazone but not 15-deoxy-Delta 12,14-prostaglandin J2 on the NFkappaB pathway in human endothelial cells.
Kaplan J; Cook JA; O'Connor M; Zingarelli B
Shock; 2007 Dec; 28(6):722-726. PubMed ID: 17621259
[TBL] [Abstract][Full Text] [Related]
16. Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice.
Jiang X; Li H; Qiao H; Jiang H; Xu R; Sun X
Cancer Sci; 2009 Nov; 100(11):2226-33. PubMed ID: 19709125
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines.
Yang YC; Tsao YP; Ho TC; Choung IP
Int J Gynecol Cancer; 2007; 17(2):418-25. PubMed ID: 17316361
[TBL] [Abstract][Full Text] [Related]
18. Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes: evidence for PPARgamma-independent inhibition by 15-deoxy-Delta12,14prostaglandin J2.
Bianchi A; Moulin D; Sebillaud S; Koufany M; Galteau MM; Netter P; Terlain B; Jouzeau JY
Arthritis Res Ther; 2005; 7(6):R1325-37. PubMed ID: 16277686
[TBL] [Abstract][Full Text] [Related]
19. Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1.
Shin SJ; Kim JY; Kwon SY; Mun KC; Cho CH; Ha E
Eur J Pharmacol; 2014 Nov; 743():17-23. PubMed ID: 25240713
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis.
Takano S; Kubota T; Nishibori H; Hasegawa H; Ishii Y; Nitori N; Ochiai H; Okabayashi K; Kitagawa Y; Watanabe M; Kitajima M
Anticancer Res; 2008; 28(6A):3593-9. PubMed ID: 19189639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
